ADC Therapeutics (ADCT) Amortization of Deferred Charges (2023 - 2026)

ADC Therapeutics has disclosed Amortization of Deferred Charges across 4 years of filings, most recently posting $225000.0 for Q1 2026.

• Amortization of Deferred Charges for Q1 2026 came in at $225000.0, up 17.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 million (up 214.24% YoY), and the FY2025 annual result was $1.8 million, up 101.77% from the prior year.
• Amortization of Deferred Charges came in at $225000.0 for Q1 2026 at ADC Therapeutics, down from $246000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $830000.0 in Q1 2023 to a low of -$557000.0 in Q4 2024.
• The 4-year median for Amortization of Deferred Charges is $516000.0 (2024), against an average of $458692.3.
• Across the five-year window, Amortization of Deferred Charges plunged 180.26% in 2024 and soared 144.17% in 2025, its largest moves.
• ADC Therapeutics' Amortization of Deferred Charges stood at $694000.0 in 2023, then sank by 180.26% to -$557000.0 in 2024, then soared by 144.17% to $246000.0 in 2025, then declined by 8.54% to $225000.0 in 2026.
• The last three Amortization of Deferred Charges figures came in at $225000.0 (Q1 2026), $246000.0 (Q4 2025), and $733000.0 (Q3 2025), per Business Quant data.